Volume 5, Issue 11, Pages 885-894 (November 2018) The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial Prof Bill Deakin, FMedSci, John Suckling, PhD, Thomas R E Barnes, DSc, Kelly Byrne, BA, Imran B Chaudhry, MD, Paola Dazzan, PhD, Richard J Drake, PhD, Annalisa Giordano, MD, Nusrat Husain, MRCPsych, Peter B Jones, MD, Eileen Joyce, MRCPsych, Emma Knox, PhD, Carl Krynicki, MSc, Stephen M Lawrie, MD, Shôn Lewis, MD, Danuta M Lisiecka-Ford, PhD, Naghmeh Nikkheslat, PhD, Carmine M Pariante, PhD, Richard Smallman, PhD, Andrew Watson, MSc, Steven C R Williams, PhD, Rachel Upthegrove, MRCPsych, Graham Dunn, PhD The Lancet Psychiatry Volume 5, Issue 11, Pages 885-894 (November 2018) DOI: 10.1016/S2215-0366(18)30345-6 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 1 Trial profile The Lancet Psychiatry 2018 5, 885-894DOI: (10.1016/S2215-0366(18)30345-6) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 2 Main outcome measures for minocycline and placebo groups The minimum scores on Positive and Negative Syndrome Scale (PANSS) subscales is 7. The Lancet Psychiatry 2018 5, 885-894DOI: (10.1016/S2215-0366(18)30345-6) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions